Interleukin-17 (IL-17) inhibitors

A compound of formula (IV), or a deuterated compound, a stereoisomer, or a pharmaceutically acceptable salt thereof:

• wherein R1 is —C(O)R11;
• R11 is selected from the group consisting of
• wherein
• are independently unsubstituted or substituted with 1, 2 or 3 R1a groups;
• the R1a groups are each independently selected from the group consisting of hydrogen, halogen, cyano, —C1-6 alkyl, halogen-substituted —C1-6 alkyl, 3- to 6-membered cycloalkyl and —C0-2 alkylene-OR1b;
• wherein R1b is selected from the group consisting of hydrogen, C1-6 alkyl and halogen-substituted C1-6 alkyl;
• R2 and R3 are independently selected from the group consisting of hydrogen and —C1-6 alkyl;
• the A ring is selected from the group consisting of
• the B ring is selected from the group consisting of
• the C ring is selected from the group consisting of
• and
• the D ring is
• RD2 and RD3 are independently selected from the group consisting of hydrogen, C1-6 alkyl, —C0-2 alkylene-ORD4, —C0-2 alkylene-(3- to 10-membered cycloalkyl), —C0-2 alkylene-(3- to 10-membered heterocycloalkyl), —C0-2 alkylene-(5- to 10-membered aromatic ring) and —C0-2 alkylene-(5- to 10-membered heteroaromatic ring);
• wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aromatic ring and heteroaromatic ring are independently unsubstituted or substituted with 1, 2 or 3 RD4 groups;
• the RD4 groups are each independently selected from the group consisting of hydrogen, C1-6 alkyl, halogen-substituted C1-6 alkyl, halogen, cyano, ═O, nitro, —OH, —O(C1-6 alkyl), —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl) (C1-6 alkyl), —C0-2 alkylene-(3- to 10-membered cycloalkyl), —C0-2 alkylene-(3- to 10-membered heterocycloalkyl), —C0-2 alkylene-(5- to 10-membered aromatic ring) and —C0-2 alkylene-(5- to 10-membered heteroaromatic ring).